OMED Profile
OncoMed
Pharmaceuticals, Inc. (OMED) is a clinical-stage biopharmaceutical
company that is focused on developing cancer treatments that target
cancer stem cells. Here's an extended company report for OncoMed
Pharmaceuticals, Inc.:
OncoMed Pharmaceuticals was founded in
2004 and is headquartered in Redwood City, California. The company's
pipeline includes several product candidates that are being developed
to treat a range of cancers, including pancreatic cancer, non-small
cell lung cancer, and breast cancer. OncoMed's lead product candidate
is vantictumab, which is being developed in partnership with Bayer AG.
The drug is designed to inhibit the activity of a signaling pathway
called the Wnt pathway, which is known to be involved in the growth
and development of cancer stem cells.
OncoMed's pipeline also
includes several other product candidates, including ipafricept,
tarextumab, and demcizumab. These drugs are being developed to target
various signaling pathways that are known to be involved in the growth
and development of cancer stem cells. The company is also developing a
companion diagnostic test that is designed to identify patients who
are most likely to respond to its cancer stem cell-targeted therapies.
As of December 31, 2021, OncoMed had approximately $31 million in
cash and cash equivalents. The company has been reliant on
partnerships and collaborations to fund its research and development
efforts, and it may need to raise additional funds in the future to
support its pipeline.
OncoMed Pharmaceuticals' stock is traded
on the NASDAQ Global Market under the ticker symbol OMED. As of March
18, 2023, the company had a market capitalization of approximately $21
million. The company faces significant competition in the
biopharmaceutical industry, and its ability to successfully develop
and commercialize its product candidates will be important to its
long-term success.
In conclusion, OncoMed Pharmaceuticals, Inc.
is a clinical-stage biopharmaceutical company that is focused on
developing cancer treatments that target cancer stem cells. The
company's pipeline includes several product candidates that are being
developed to treat a range of cancers, and its lead product candidate
is being developed in partnership with Bayer AG. OncoMed faces
significant competition in the biopharmaceutical industry, and its
ability to successfully develop and commercialize its product
candidates will be important to its long-te
|
